The Patent Finder

Innate Pharma

49 patents currently held · Updated Nov 21, 2026
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

3
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 30, 2026
    The maintenance fee for Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders (US 9,067,997) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
  • 1 fee due Jan 9, 2027
    The maintenance fee for Treatment of Peripheral T Cell Lymphoma (US 10,344,087) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
  • 1 fee due Apr 24, 2027
    The maintenance fee for Treatment of Head and Neck Cancer (US 11,795,222) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
  • 2 fees due Jun 19 to 30, 2027 · next Jun 19
  • 1 fee due Jul 2, 2027
    The maintenance fee for KIR3DL2 Binding Agents (US 11,858,990) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Aug 6, 2027
    The maintenance fee for Variable regions for NKp46 binding proteins (US 11,891,444) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
  • 1 fee due Sep 3, 2027
    The maintenance fee for KIR3DL2 Binding Agents (US 10,577,419) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
  • 2 fees due Oct 16 to 30, 2027 · next Oct 16

Which patents, and when each one lapses · Pro

Recent changes

  • 2 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,732,131Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
In force
 · USPTO record
In forceUSPTO record
US 10,160,810Monoclonal antibodies against NKG2A
In force
 · USPTO record
In forceUSPTO record
US 8,993,319Monoclonal antibodies against NKG2A
In force
 · USPTO record
In forceUSPTO record
US 9,067,997Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders
In force
 · USPTO record
In forceUSPTO record
US 10,675,359Enzymatic conjugation of antibodies
In force
 · USPTO record
In forceUSPTO record
US 10,688,180Combination of Anti-Kir and ANTI-CTLA-4 Antibodies to Treat Cancer
In force
 · High confidence
In forceHigh confidence
US 10,344,087Treatment of Peripheral T Cell Lymphoma
In force
 · High confidence
In forceHigh confidence
US 11,999,784Treatment of Peripheral T Cell Lymphoma
In force
 · High confidence
In forceHigh confidence
US 10,174,112Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
In force
 · USPTO record
In forceUSPTO record
US 11,078,275Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
In force
 · USPTO record
In forceUSPTO record
10 of 49 patents shown.
Pro members see all 49.
Pro members: see all 49 patents
Also on record, not counted in the 49: 14 patents in force now held by others · 25 lapsed for an unpaid fee · 10 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

18 pending · 14 abandoned · 49 no status recorded

Rows 11 to 60 of 81 are for members. The first 10 are on the company page.
Pro members see all 81 published applications.
Upgrade to Pro
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited